SpringerLink
Log in

Hypocretin Ligand Deficiency in Narcolepsy: Recent Basic and Clinical Insights

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep paralysis. Both sporadic and familial forms exist in humans. Recently, the major pathophysiology of human narcolepsy was indicated, based on discovery, through animal study, of narcolepsy genes involved in the pathology of hypocretin/orexin ligand and its receptor. Hypocretin ligand deficiency is found in most patients with narcolepsy with cataplexy. This deficiency likely is the result of postnatal cell death of hypocretin neurons, and involvement of autoimmune mechanisms is suggested. Hypocretin deficiency also is found in symptomatic narcolepsy and excessive daytime sleepiness with neurologic conditions, including immune-mediated neurologic disorders. These findings have significant clinical relevance and promote understanding of hypocretin cell death mechanisms. Already, discoveries in humans have led to a new diagnostic test for narcolepsy. Currently, hypocretin replacement therapy has emerged as a promising therapeutic option, and experiments using gene therapy and cell transplantation are in progress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Nishino S, Kanbayashi T: Symptomatic narcolepsy, cataplexy, and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005, 9:269–310.

    Article  PubMed  Google Scholar 

  2. • Nishino S: Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007, 8:373–399. The author examines the centrality of hypocretin neurotransmission impairment to the pathophysiologic mechanism in narcolepsy and the potential of ligand replacement as a relevant therapeutic option in view of the results of recent animal studies.

  3. Mignot E, Lammers GJ, Ripley B, et al.: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553–1562.

    Article  PubMed  Google Scholar 

  4. Nishino S: The hypocretin/orexin system in health and disease. Bio Psychiatry 2003, 54:87–95.

    Article  CAS  Google Scholar 

  5. Nishino S, Mignot E: Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997, 52:27–78.

    Article  CAS  PubMed  Google Scholar 

  6. Nishino S, Taheri S, Black J, et al.: The neurobiology of sleep in relation to mental illness. In Neurobiology of Mental Illness. Edited by Charney DS, Nestler EJ. New York: Oxford University Press; 2004:1160–1179.

  7. Espana RA, Scammell TE: Sleep neurobiology for the clinician. Sleep 2004, 27:811–820.

    PubMed  Google Scholar 

  8. Aldrich MS, Chervin RD, Marlow BA: Value of the multiple sleep latency test (MSLT) for diagnosis of narcolepsy. Sleep 1997, 20:620–629.

    CAS  PubMed  Google Scholar 

  9. Takeuchi T, Miyasist A, Sasaki Y, et al.: Isolated sleep paralysis elicited by sleep interruption. Sleep 1992, 15:217–225.

    CAS  PubMed  Google Scholar 

  10. Sakurai T, Amemiya A, Ishii M, et al.: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573–585.

    Article  CAS  PubMed  Google Scholar 

  11. De Lecca L, Kilduff TS, Peyron C, et al.: The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322–327.

    Article  Google Scholar 

  12. Peyron C, Tighe DK, van den Pol AN, et al.: Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998, 18:9996–10015.

    CAS  PubMed  Google Scholar 

  13. Lin L, Faraco J, Li R, et al.: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365–376.

    Article  CAS  PubMed  Google Scholar 

  14. Chemelli RM, Willie JT, Sinton CM, et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437–451.

    Article  CAS  PubMed  Google Scholar 

  15. Nishino S, Ripley B, Overeem S, et al.: Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39–40.

    Article  CAS  PubMed  Google Scholar 

  16. Peyron C, Faraco J, Rogers W, et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991–997.

    Article  CAS  PubMed  Google Scholar 

  17. Nishino S, Ripley B, Overeen S, et al.: Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001, 50:381–388.

    Article  CAS  PubMed  Google Scholar 

  18. American Academy of Sleep Medicine: The International Classification of Sleep Disorders Diagnostic and Coding Manual, edn 2. Winchester, IL: American Academy of Sleep Medicine; 2005.

    Google Scholar 

  19. Honda Y: Clinical features of narcolepsy: Japanese experience. In HLA in Narcolepsy. Edited by Honda Y, Juji T. New York: Springer-Verlag; 1988:24–57.

  20. Kanbayashi T, Inoue Y, Chiba S, et al.: CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002, 11:91–93.

    Article  PubMed  Google Scholar 

  21. Blouin AM, Thannickal TC, Worley PF, et al.: Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 2005, 65:11189–11192.

    Article  CAS  Google Scholar 

  22. Crocker A, Espana RE, Papdopoulou M, et al.: Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005, 65:1184–1188.

    Article  CAS  PubMed  Google Scholar 

  23. • Honda M, Eriksson KS, Zhang S, et al.: IGFBP3 colocalizes with and regulates hypocretin (orexin). PLoS One 2009, 4:e4254. This article discusses the recent identification of IGFBP3, thereby underscoring selective hypocretin cell death, as opposed to transcription/biosynthesis or hypocretin peptide processing problems, as the cause of hypocretin deficiency.

  24. Billiard M, Laaberki MF, Reygrobellet C, et al.: Elevated antibodies to streptococcal antigens in narcoleptic subjects. Sleep Res 1989, 18:201.

    Google Scholar 

  25. • Dauvilliers Y, Arnulf I, Mignot E: Narcolepsy with cataplexy. Lancet 2007, 369:499–511. This article discusses the possibility that transient autoimmune reaction in the CNS coincides with disease onset despite the failure to find typical autoimmune pathologies or to implicate neuron-specific/organ-specific autoimmune antibodies or IgG reactive to prepro-hypocretin or cleavage products in narcoleptic patients.

  26. • Aran A, Lin L, Nevsimalova S, et al.: Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009, 32(8):979–983. This recent, significant study evaluated Streptococcus pyogenes and Helicobacter pylori infections as triggers for narcolepsy. The study compared 200 hypocretin-deficient narcolepsy patients with 200 age-matched controls to find that patients exhibited significantly higher immune response markers close to narcolepsy onset. These findings underscore the probability that streptococcal infections are significant environmental triggers for narcolepsy.

  27. Mignot E: Genetic and familial aspects of narcolepsy. Neurology 1998, 50:S16–S22.

    CAS  PubMed  Google Scholar 

  28. Hohjoh H, Nakayama T, Ohashi J, et al.: Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy. Tissue Antigens 2000, 56:446–448.

    Article  CAS  PubMed  Google Scholar 

  29. Dauvilliers Y, Neidhart E, Lecendreux M, et al.: MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 2001, 6:367–372.

    Article  CAS  PubMed  Google Scholar 

  30. • Miyagawa T, Kawashima M, Nishida N, et al.: Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 2008, 40:1324–1328. These familial and twin studies examining gene polymorphisms associated with narcolepsy specifically indicate that the predictive genes of narcolepsy may exacerbate narcolepsy sleep phenotype and/or engage mechanisms of hypocretin cell death.

  31. Park MH, Roh EY, Park H, et al.: Association of TNF-alpha gene promoter polymorphism with narcolepsy-cataplexy in Koreans. Hum Immunol 2004, 65:S110.

    Article  Google Scholar 

  32. Wieczorek S, Gencik M, Rujescu D, et al.: TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 2003, 61:437–442.

    Article  CAS  PubMed  Google Scholar 

  33. Dickenstein JB, Moldofsky H, Lue FA, et al.: Intracerebroventricular injection of TNF-alpha promotes sleep and is recovered in cervical lymph. Am J Physiol 1999, 276:R1018–R1022.

    Google Scholar 

  34. Kawashima M, Tamiya G, Oka A, et al.: Genomewide association analysis of human narcolepsy and a new resistance gene. Am J Hum Genet 2006, 79:252–263.

    Article  CAS  PubMed  Google Scholar 

  35. Tafti M, Petit B, Chollet D, et al.: Deficiency in short-chain fatty acid beta-oxidation affects theta oscillations during sleep. Nat Genet 2003, 34:320–325.

    Article  CAS  PubMed  Google Scholar 

  36. Hallmayer J, Faraco J, Lin L, et al.: Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009, 41:708–711.

    Article  CAS  PubMed  Google Scholar 

  37. • Verma A, Anand V, Verma NP: Sleep disorders in chronic traumatic brain injury. J Clin Sleep Med 2007, 3:357–362. This article identifies percentages of US patients among several million with chronic brain injury who report sleep problems and symptomatic EDS, underscoring the clinical relevance of symptomatic EDS.

  38. Scammell TE, Nishino S, Mignot E, et al.: Narcolepsy and low CFS orexin (hypocretin) concentration after diencephalic stroke. Neurology 2001, 56:1751–1753.

    CAS  PubMed  Google Scholar 

  39. Marcus CL, Trescher WH, Halbower AC, et al.: Secondary narcolepsy in children with brain tumors. Sleep 200, 25:435–459.

  40. Nishino S, Kanbayashi T, Fujiki N, et al.: CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 2003, 61:823–825.

    CAS  PubMed  Google Scholar 

  41. Overeem S, Dalmau J, Bataller L, et al.: Secondary narcolepsy in patients with paraneoplastic anti-Ma2 antibodies is associated with hypocretin deficiency. J Sleep Res 2001, 11(Suppl.1):166–167.

    Google Scholar 

  42. • Kanbayashi T, Shimohata T, Nakashima I, et al.: Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009, 66(12):1563–1566. The authors report a significant recent study of symptomatic narcolepsy in patients diagnosed with immune-mediated neurologic condition MS with bilateral hypothalamic inflammatory lesions. The findings specifically link the presence of anti-AQP4 antibody and the probability of immuno-attack in hypothalamic periventricular regions to reduced CSF hypocretin-1 levels. Further, they suggest that additional antibody-mediated mechanisms also contribute to secondary hypocretin system impairment, manifesting in EDS symptoms.

  43. Ripley B, Fujiki N, Okura M, et al.: CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253–2258.

    CAS  PubMed  Google Scholar 

  44. Tachibana N, Howar RS, Hirsch NP, et al.: Sleep problems in multiple sclerosis. Eur Neurol 1994, 34:320–323.

    Article  CAS  PubMed  Google Scholar 

  45. Amiry-Moghaddam M, Ottersen, OP: The molecular basis of water transport in the brain. Nat Rev Neurosci 2003, 4:991–1001.

    Article  CAS  PubMed  Google Scholar 

  46. Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473–477.

    Article  CAS  PubMed  Google Scholar 

  47. Fujiki N, Ripley B, Yoshida Y, et al.: Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 2003, 6:953–959.

    Google Scholar 

  48. Mieda M, Willie JT, Hara J, et al.: Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004, 101:4649–4654.

    Article  CAS  PubMed  Google Scholar 

  49. • Mishima K, Fujiki N, Yoshida Y, et al.: Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep 2008, 31:1119–1126. This study demonstrated that supplementation of hypocretin-1 by central administration normalized sleep/wake patterns and behavioral arrest episodes in hypocretin cell–ablated narcoleptic (orexin/ataxin-3) mice. It further demonstrated that exogenous expression of the prepro-hypocretin gene rescued sleep fragmentation and cataplexy in the mice, thus supporting further research aimed toward develo** cell transplantation and gene therapy treatment options.

  50. Ripley B, Fujiki N, Okura M, et al.: Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001, 8:525–534.

    Article  CAS  PubMed  Google Scholar 

  51. Schatzberg SJ, Cutter-Schatzberg K, Nydam D, et al.: Case study: effect of hypocretin ligand replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med 2004, 18:586–588.

    Article  PubMed  Google Scholar 

  52. Liu M, Thankachan S, Kaur S, et al.: Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci 2008, 28:1382–1393.

    Article  PubMed  Google Scholar 

  53. Arias-Carrion O, Murillo-Rodriguez E, Xu M, et al.: Transplant of hypocretin neurons into the pontine reticular formation: primary results. Sleep 2004, 27:1465–1470.

    PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Center for Narcolepsy, Stanford School of Medicine, Stanford University Sleep and Circadian Neurobiology Laboratory, 1201 Welch Road, MSLS, P213, Palo Alto, CA, 94304, USA

    Cayde Ritchie, Masashi Okuro & Seiji Nishino

  2. Department of Neuropsychiatry, Akita University School of Medicine, Akita, Japan

    Takashi Kanbayashi

Authors
  1. Cayde Ritchie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masashi Okuro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Kanbayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seiji Nishino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seiji Nishino.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ritchie, C., Okuro, M., Kanbayashi, T. et al. Hypocretin Ligand Deficiency in Narcolepsy: Recent Basic and Clinical Insights. Curr Neurol Neurosci Rep 10, 180–189 (2010). https://doi.org/10.1007/s11910-010-0100-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-010-0100-z

Keywords

Search

Navigation